One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Incidence, Timing, and Factors Associated With Suicide Among Patients Undergoing Surgery for Cancer in the US
Alexandra L. Potter, BS1; Chinmay Haridas, MBBS1; Krista Neumann, BMath2; Mathew V. Kiang, ScD3; Zhi Ven Fong, MD, MPH4; Corinne A. Riddell, PhD, MSc2,5; Harrison G. Pope Jr, MD, MPH6,7; Chi-Fu Jeffrey Yang, MD1
doi : 10.1001/jamaoncol.2022.6549
Importance The risk and timing of suicide among patients who undergo surgery for cancer remain largely unknown, and, to our knowledge, there are currently no organized programs in place to implement regular suicide screening among this patient population.
Association of Adjuvant Chemotherapy in Patients With Resected Pancreatic Adenocarcinoma After Multiagent Neoadjuvant Chemotherapy
Toshitaka Sugawara, MD, PhD1,2; Salvador Rodriguez Franco, MD1; Samantha Sherman, MD3; Michael J. Kirsch, MD, MS4; Kathryn Colborn, PhD, MSPH5,6; Jun Ishida, MD, PhD1; Samuele Grandi, MD1; Mohammed H. Al-Musawi, MD, MBChB, MSc7; Ana Gleisner, MD, PhD1,8; Richard D. Schulick, MD, MBA4,8; Marco Del Chiaro, MD, PhD1,8
doi : 10.1001/jamaoncol.2022.5808
Importance The total number of patients with pancreatic ductal adenocarcinoma (PDAC) who receive neoadjuvant chemotherapy (NAC) is increasing. However, the added role of adjuvant chemotherapy (AC) in these patients remains unknown.
Adoption of Innovative Therapies Across Oncology Practices—Evidence From Immunotherapy
Caitlin E. Carroll, PhD1; Mary Beth Landrum, PhD2; Alexi A. Wright, MD, MPH3; Nancy L. Keating, MD, MPH2,4
doi : 10.1001/jamaoncol.2022.6296
Importance Immunotherapies reflect an important breakthrough in cancer treatment, substantially improving outcomes for patients with a variety of cancer types, yet little is known about which practices have adopted this novel therapy or the pace of adoption.
Association Between Age and Survival Trends in Advanced Non–Small Cell Lung Cancer After Adoption of Immunotherapy
Teja Voruganti, MD, PhD1; Pamela R. Soulos, MPH2; Ronac Mamtani, MD3; Carolyn J. Presley, MD, MHS4; Cary P. Gross, MD2,5
doi : 10.1001/jamaoncol.2022.6901
Importance The introduction of immune checkpoint inhibitors (ICIs) has transformed the care of advanced non–small cell lung cancer (NSCLC). Although clinical trials suggest substantial survival benefits, it is unclear how outcomes have changed in clinical practice.
Atezolizumab Plus Bevacizumab as First-line Treatment for Patients With Metastatic Nonsquamous Non–Small Cell Lung Cancer With High Tumor Mutation Burden
Mariano Provencio, MD, PhD1; Ana Laura Ortega, MD2; Juan Coves-Sarto, MD3; Virginia Calvo, MD, PhD1; Raquel Marsé-Fabregat, MD4; Manuel Dómine, MD, PhD5; MarÃa Guirado, MD6; Enric Carcereny, MD7; Natalia Fernández, MD8; Ruth Ã�lvarez, MD9; Remei Blanco, MD10; Luis León-Mateos, MD11; José Miguel Sánchez-Torres, MD12; Ivana Gabriela Sullivan, MD, PhD13; Manuel Cobo, MD, PhD14; Alfredo Sánchez-Hernández, MD, PhD15; Bartomeu Massuti, MD16; Belen Sierra-Rodero, MSc1; Cristina Mártinez-Toledo, MSc1; Roberto Serna-Blasco, MSc1; Atocha Romero, PhD1; Alberto Cruz-Bermúdez, PhD1
doi : 10.1001/jamaoncol.2022.5959
Question What are the outcomes of atezolizumab plus bevacizumab for treatment of patients with advanced nonsquamous non–small cell lung cancer (NSCLC) with high tumor mutation burden?
Trends in the Characteristics, Treatment, and Outcomes of Rectal Adenocarcinoma in the US From 2004 to 2019
Sameh H. Emile, MBBCh, MSc, MD1,2; Nir Horesh, MD1,3; Michael R. Freund, MD1,4; Zoe Garoufalia, MD1; Rachel Gefen, MD1,5; Emanuela Silva-Alvarenga, MD1; David J. Maron, MD1; Giovanna DaSilva, MD1; Steven D. Wexner, MD1
doi : 10.1001/jamaoncol.2022.6116
Importance Rectal cancer management has significantly evolved over the last 2 decades.
Magnetic Resonance Imaging–Guided vs Computed Tomography–Guided Stereotactic Body Radiotherapy for Prostate Cancer
Amar U. Kishan, MD1,2; Ting Martin Ma, MD, PhD1; James M. Lamb, PhD1; Maria Casado, BS1; Holly Wilhalme, MSc3; Daniel A. Low, PhD1; Ke Sheng, PhD1; Sahil Sharma, BS1; Nicholas G. Nickols, MD, PhD1,2; Jonathan Pham, PhD1; Yingli Yang, PhD1; Yu Gao, PhD1; John Neylon, PhD1; Vincent Basehart, BS1; Minsong Cao, PhD1; Michael L. Steinberg, MD1
doi : 10.1001/jamaoncol.2022.6558
Importance Magnetic resonance imaging (MRI) guidance offers multiple theoretical advantages in the context of stereotactic body radiotherapy (SBRT) for prostate cancer. However, to our knowledge, these advantages have yet to be demonstrated in a randomized clinical trial.
Malignant Neoplasms of the Gastrointestinal Tract After Blood or Marrow Transplant
Andrew McDonald, MD, MS1,2; Chen Dai, MS1; Qingrui Meng, MS1; Lindsey Hageman, MPH1; Joshua Richman, MD, PhD1; Jessica Wu, MPH1; Liton Francisco, BS1; Elizabeth Ross, MBA1; Nora Balas, MSPH1; Alysia Bosworth, BA3; Hok Sreng Te, BA4; F. Lennie Wong, PhD3; Wendy Landier, PhD, RN1,5; Donna Salzman, MD6; Ravi Bhatia, MD6; Daniel J. Weisdorf, MD4; Stephen J. Forman, MD7; Saro H. Armenian, DO, MPH3; Smita Bhatia, MD, MPH1,5
doi : 10.1001/jamaoncol.2022.6569
Importance Survivors of blood or marrow transplant (BMT) are at increased risk of subsequent malignant neoplasms (SMNs). Cancers of the gastrointestinal (GI) system are of special interest because their clinical behavior is often aggressive, necessitating early detection by increasing awareness of high-risk populations.
Association of COVID-19 Vaccination With Breakthrough Infections and Complications in Patients With Cancer
Inna Y. Gong, MD, PhD1; Abi Vijenthira, MD, SM1,2; Melanie Powis, MSc2,3; Andrew Calzavara, MSc4; Aditi Patrikar, MSPH4; Rinku Sutradhar, PhD4,5; Lisa K. Hicks, MD, MSc1,6; Drew Wilton, MS4; Simron Singh, MD, MPH1,4,7; Monika K. Krzyzanowska, MD, MPH1,2,3,4; Matthew C. Cheung, MD, SM1,4,7
doi : 10.1001/jamaoncol.2022.6815
Importance Patients with cancer are known to have increased risk of COVID-19 complications, including death.
Long-term Trajectories of Physical Function Decline in Women With and Without Cancer
Elizabeth M. Cespedes Feliciano, ScD, SM1; Sowmya Vasan, MS2; Juhua Luo, PhD3; Alexandra M. Binder, ScD4,5; Rowan T. Chlebowski, MD, PhD6; Charles Quesenberry, PhD1; Hailey R. Banack, PhD7,8; Bette J. Caan, DrPH1; Electra D. Paskett, PhD9; Grant R. Williams, MD, MSPH10; Ana Barac, MD, PhD11; Andrea Z. LaCroix, PhD12; Ulrike Peters, PhD2; Kerryn W. Reding, PhD, MPH13; Kathy Pan, MD6; Aladdin H. Shadyab, PhD, MS, MPH12; Lihong Qi, PhD14; Garnet L. Anderson, PhD2
doi : 10.1001/jamaoncol.2022.6881
Importance Patients with cancer experience acute declines in physical function, hypothesized to reflect accelerated aging driven by cancer-related symptoms and effects of cancer therapies. No study has examined long-term trajectories of physical function by cancer site, stage, or treatment compared with cancer-free controls.
Association of Inflammatory Biomarkers With Survival Among Patients With Stage III Colon Cancer
En Cheng, MD, PhD1; Qian Shi, PhD2; Anthony F. Shields, MD, PhD3; Andrew B. Nixon, PhD, MBA4; Ardaman P. Shergill, MD5; Chao Ma, MS6; Katherine A. Guthrie, PhD7; Felix Couture, MD8; Philip Kuebler, MD9; Pankaj Kumar, MD10; Benjamin Tan, MD11; Smitha S. Krishnamurthi, MD12; Kimmie Ng, MD, MPH6; Eileen M. O’Reilly, MD13; Justin C. Brown, PhD14; Philip A. Philip, MD, PhD3; Bette J. Caan, DrPH1; Elizabeth M. Cespedes Feliciano, ScD, ScM1; Jeffrey A. Meyerhardt, MD, MPH6
doi : 10.1001/jamaoncol.2022.6911
Importance The association of chronic inflammation with colorectal cancer recurrence and death is not well understood, and data from large well-designed prospective cohorts are limited.
Long-term Effect of Machine Learning–Triggered Behavioral Nudges on Serious Illness Conversations and End-of-Life Outcomes Among Patients With Cancer
Christopher R. Manz, MD1,2; Yichen Zhang, PhD3; Kan Chen, MA4; Qi Long, PhD4; Dylan S. Small, PhD5; Chalanda N. Evans, BS6; Corey Chivers, PhD7; Susan H. Regli, PhD7; C. William Hanson, MD7; Justin E. Bekelman, MD3,8; Jennifer Braun, MHA, RN, BSN7; Charles A. L. Rareshide, MS6; Nina O’Connor, MD6; Pallavi Kumar, MD, MPH6,9; Lynn M. Schuchter, MD6,8; Lawrence N. Shulman, MD6,8; Mitesh S. Patel, MD, MBA10; Ravi B. Parikh, MD, MPP3,6,8,9
doi : 10.1001/jamaoncol.2022.6303
Importance Serious illness conversations (SICs) between oncology clinicians and patients are associated with improved quality of life and may reduce aggressive end-of-life care. However, most patients with cancer die without a documented SIC.
Rechallenge After Oxaliplatin-Induced Hypersensitivity Reactions
Elie Rassy, MD1; Florence Le Roy, MD1,2; Cristina Smolenschi, MD1; Marine Valéry, MD1; Valérie Boige, MD, PhD1; Michel Ducreux, MD, PhD1,3; Alice Boilève, MD1,3
Emerging Strategies for the Treatment of Small Cell Lung Cancer
W. Jeffrey Petty, MD1; Luis Paz-Ares, MD2,3,4
doi : 10.1001/jamaoncol.2022.5631
Importance Small cell lung cancer (SCLC) is an aggressive disease that is characterized by rapid growth and the early development of metastases. Patients typically respond to initial chemotherapy but quickly experience relapse, resulting in a poor long-term outcome. Therapeutic innovations that substantially improve survival have historically been limited, and reliable, predictive biomarkers are lacking.
Endocrine Society Hypercalcemia of Malignancy Guidelines
Laura T. Dickens, MD1; Ben Derman, MD2; Jason T. Alexander, MD3
A Case of Multiple Hemorrhagic Friable Nodules
Carrie Diamond, BA1; Rami N. Al-Rohil, MBBS2,3; Adela R. Cardones, MD, MHSc4
Chimeric Antigen Receptor T-Cell Therapy for Patients With Multiple Myeloma—A Call for Equal Opportunity
Mendel Goldfinger, MD1; Nishi Shah, MD1; Dennis L. Cooper, MD1
Re-envisioning the Paradigm for Oncology Electronic Health Record Documentation by Paying for What Matters for Patients, Quality, and Research
Peter E. Gabriel, MD1; Aditi P. Singh, MD2; Lawrence N. Shulman, MD1
Neoadjuvant Immunotherapy for Patients With Non–Small Cell Lung Cancer—Is a New Era Coming?
Bo Zhang, PhD1; Hua Zhong, PhD1; Baohui Han, PhD, MD1
Evidence-Based Strategies to Reduce Suicide Mortality Among Patients With Cancer
Craig J. Bryan, PsyD, ABPP1; Kristen M. Carpenter, PhD1; Timothy M. Pawlik, MD, PhD, MPH, MTS, MBA2
Adjuvant Therapy for Pancreatic Adenocarcinoma—Leaving No Rock Unturned
Meredith C. Mason, MD1; Maria C. Russell, MD1; Nader N. Massarweh, MD, MPH1,2,3
First-line Immunotherapy and Clinically Meaningful Survival Benefits for the Oldest Adults With Lung Cancer
Marjory Charlot, MD1; Jhanelle E. Gray, MD2
Atezolizumab Plus Bevacizumab in TMB-High Non−Small Cell Lung Cancers—The Hunt for Predictive Biomarkers to Optimize Treatment Selection
Biagio Ricciuti, MD1; Mark M. Awad, MD, PhD1
The MIRAGE Trial—Optical Illusion or the Future of Prostate Stereotactic Radiotherapy?
Shankar Siva, PhD, MBBS1,2; Piet Ost, PhD, MD3,4; Muhammad Ali, MBBS1,2
Adolescents and Young Adults With Cancer
Ilit Turgeman, MD1; Howard (Jack) West, MD2
Overall Survival With Adjuvant mFOLFIRINOX for Pancreatic Cancer
Michele Reni, MD1; Marina Macchini, MD, PhD1; Luca Porcu, MD2
Overall Survival With Adjuvant mFOLFIRINOX for Pancreatic Cancer—Reply
Thierry Conroy, MD1; Florence Castan, MSc2; Pascal Hammel, MD, PhD3
